查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1918104

自体免疫疾病检测市场—2026-2031年预测

Autoimmune Disease Testing Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

自体免疫疾病检测市场预计将从 2025 年的 58.43 亿美元成长到 2031 年的 89.29 亿美元，复合年增长率为 7.32%。

自体免疫疾病检测市场正经历显着成长，这主要受疾病盛行率上升和诊断技术进步的推动。自体免疫疾病的特征是身体对自身组织产生异常免疫反应，破坏正常的免疫稳态，通常涉及发炎、自体抗体和自体反应性T细胞。由于这些疾病的复杂性以及缺乏单一的确诊检测方法，因此需要先进的诊断方法来辅助患者管理、预后评估和器官受累情况的判断。

市场成长的关键驱动因素是全球自体免疫疾病盛行率的上升。儿童族群中第1型糖尿病和老年族群中类风湿性关节炎（RA）等疾病发生率的增加，持续推高了对诊断解决方案的需求。全球人口老化进一步加速了这一趋势，老化扩大了RA等与老龄化相关的自体免疫疾病的患者群体，直接推动了检测需求。

同时，民众和医疗专业人员对自体免疫疾病的认知不断提高，也推动了市场成长。诸如特定宣传月和以患者为中心的教育宣传活动等倡议，提高了人们对疾病症状的认识，并强调了早期诊断的重要性。这种对早期检测的日益重视对于改善患者预后至关重要，也是推动诊断测试需求的主要因素。

市场按检测类型和疾病进一步细分，某些领域展现出显着的成长潜力。抗核抗体 (ANA) 检测预计将成为高成长细分市场，因为它有助于在临床症状出现之前早期发现疾病。与传统方法相比，ANA 检测操作简单且准确，已被广泛采用作为一线检测方法，直接推动了市场扩张。同样，全身性红斑性狼疮(SLE) 检测细分市场也预计将占据相当大的市场份额。对复杂系统性自体免疫疾病诊断需求的不断增长，正促使诊断公司开发和推出专门的检测方法，从而丰富其产品线并加速市场成长。

全球免疫诊断市场涵盖医院、诊断实验室和研究机构等，为自体免疫检测提供了坚实的基础。医院仍然是主要的终端用户，其综合诊疗模式整合了先进的诊断和治疗，因此备受认可。在公共和私人资金的支持下，这些机构不断采用尖端方法和医疗设备，从而提高了医疗服务标准，并维持了高水准的检测量。

从地理上看，亚太地区预计将主导自体免疫疾病检测市场。这一主导地位归因于该地区某些自体免疫疾病（例如全身性红斑性狼疮）的高发病率和不断上升的趋势。市场参与企业的策略性倡议、持续的研发投入以及医疗基础设施的不断完善是巩固该地区市场份额的关键因素。

竞争格局相对集中，主要由雅培、生物梅里埃和赛默飞世尔科技等全球知名企业主导。这些公司透过持续的研发投入和策略扩张，维持了市场领先地位。一个显着的趋势是，诊断公司正与医院网路建立策略联盟，以满足不同地区庞大的患者群体和多样化的检测需求。预计这项策略将持续发展并影响市场走向。这种对创新和合作的重视凸显了市场的活力和应对力，并预示着其将持续扩张。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章自体免疫疾病检测市场（依产品类型划分）

  • 介绍
  • 装置
    • 分析器
    • 流式细胞仪
    • 其他的
  • 试剂和耗材

第六章自体免疫疾病检测市场（依检测类型划分）

  • 介绍
  • 抗核抗体（ANA）检测
  • C反应蛋白检测
  • 类风湿因子
  • 抗中共抗体检测
  • 其他的

第七章自体免疫疾病检测市场（依疾病类型划分）

  • 介绍
  • 类风湿性关节炎
  • 狼疮
  • 硬皮症
  • 血管炎
  • 发炎性肠道疾病
  • 其他的

第八章自体免疫疾病检测市场（按最终用户划分）

  • 介绍
  • 医院和诊所
  • 诊断中心
  • 其他的

第九章 各地区自体免疫疾病检测市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十一章：公司简介

  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics Incorporated
  • Abbott
  • Werfen
  • Trinity Biotech Plc
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Exagen Inc

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615574

The autoimmune disease testing market is projected to expand at a 7.32% CAGR, attaining USD 8.929 billion in 2031 from USD 5.843 billion in 2025.

The autoimmune disease testing market is experiencing significant growth, driven by increasing disease prevalence and advancements in diagnostic capabilities. Autoimmune diseases, characterized by an aberrant immune response against the body's own tissues, disrupt normal immunological homeostasis and are typically marked by inflammation, autoantibodies, and self-reactive T cells. The complexity of these conditions, for which no single definitive laboratory test exists, necessitates a sophisticated diagnostic approach to aid in patient management, prognosis, and assessment of organ involvement.

A primary catalyst for market expansion is the rising global prevalence of autoimmune disorders. The increasing incidence of conditions such as type 1 diabetes in pediatric populations and rheumatoid arthritis (RA) in the growing geriatric demographic is creating a substantial and sustained demand for diagnostic solutions. This trend is compounded by a global aging population, which presents a larger patient base for age-related autoimmune conditions like RA, thereby directly fueling the need for testing.

Concurrently, heightened awareness of autoimmune diseases among both the public and healthcare professionals is bolstering market growth. Initiatives such as dedicated awareness months and patient-focused education campaigns are improving recognition of disease symptoms and underscoring the importance of early diagnosis. This growing emphasis on early detection is critical for improving patient outcomes and is a key factor propelling the demand for diagnostic testing.

The market is further segmented by test type and disease focus, with specific areas demonstrating pronounced growth potential. The antinuclear antibody (ANA) test is anticipated to be a high-growth segment due to its utility in early disease detection, often before clinical symptoms manifest. The test's procedural simplicity and accuracy compared to older methods make it a widely adopted first-line tool, directly contributing to market expansion. Similarly, the segment for Systemic Lupus Erythematosus (SLE) testing is expected to hold a significant market share. The drive to diagnose complex systemic autoimmune disorders has prompted diagnostic companies to develop and launch specialized assays, thereby enriching the product landscape and accelerating market growth.

The broader global immune diagnostics market, encompassing hospitals, diagnostic facilities, and research organizations, provides a robust infrastructure for autoimmune testing. Hospitals remain the dominant end-user setting, favored for their comprehensive care models that integrate advanced diagnostics with treatment. The continuous adoption of cutting-edge procedures and medical equipment within these institutions, often supported by public and private funding, elevates the standard of care and sustains a high volume of testing.

Geographically, the Asia-Pacific region is anticipated to dominate the autoimmune disease testing market. This leadership is attributed to a high and growing prevalence of specific autoimmune conditions, such as systemic lupus erythematosus, within the region. Strategic initiatives by market participants, ongoing research investments, and the continuous development of healthcare infrastructure are key factors consolidating the region's substantial market share.

The competitive landscape is relatively concentrated and features established global players such as Abbott Laboratories, BioMerieux, and Thermo Fisher Scientific. These companies maintain their market leadership through sustained investment in research and development and strategic expansion efforts. A notable trend involves diagnostic firms forming strategic alliances with hospital networks to address high patient volumes and diverse testing needs across different geographies, a strategy expected to persist and shape the market's trajectory. This focus on innovation and collaboration underscores a dynamic and responsive market poised for continued expansion.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Autoimmune Disease Testing Market Segmentation:

  • By Product Type
  • Instruments
  • Analyzers
  • Flow Cytometers
  • Others
  • Reagents & Consumables
  • By Test Type
  • Antinuclear Antibody (ANA) Test
  • C-Reactive Protein Test
  • Rheumatoid Factor
  • Anti-CCP Test
  • Others
  • By Disease Type
  • Rheumatoid Arthritis
  • Lupus
  • Scleroderma
  • Vasculitis
  • Inflammatory Bowel Disease
  • Others
  • By End-User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. AUTOIMMUNE DISEASE TESTING MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Instruments
    • 5.2.1. Analyzers
    • 5.2.2. Flow Crytometers
    • 5.2.3. Others
  • 5.3. Reagents & Consumables

6. AUTOIMMUNE DISEASE TESTING MARKET BY TEST TYPE

  • 6.1. Introduction
  • 6.2. Antinuclear Antibody (ANA) Test
  • 6.3. C-Reactive Protein Test
  • 6.4. Rheumatoid Factor
  • 6.5. Anti-CCP Test
  • 6.6. Others

7. AUTOIMMUNE DISEASE TESTING MARKET BY DISEASE TYPE

  • 7.1. Introduction
  • 7.2. Rheumatoid Arthritis
  • 7.3. Lupus
  • 7.4. Scleroderma
  • 7.5. Vasculitis
  • 7.6. Inflammatory Bowel Disease
  • 7.7. Others

8. AUTOIMMUNE DISEASE TESTING MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Diagnostic Centers
  • 8.4. Others

9. AUTOIMMUNE DISEASE TESTING MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Italy
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. F. Hoffmann-La Roche Ltd
  • 11.2. Siemens Healthcare GmbH
  • 11.3. Thermo Fisher Scientific Inc.
  • 11.4. Quest Diagnostics Incorporated
  • 11.5. Abbott
  • 11.6. Werfen
  • 11.7. Trinity Biotech Plc
  • 11.8. Bio-Rad Laboratories, Inc.
  • 11.9. Danaher Corporation
  • 11.10. Exagen Inc

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations